PDE7 inhibitors as new drugs for neurological and inflammatory disorders

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 10, 2008, Pages 1127-1139

  Gil, Carmen ^a   Campillo, Nuria E ^a   Perez, Daniel I ^b   Martinez, Ana ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Dual PDE7 PDE4 inhibitors; Inflammatory diseases; Neurological diseases; PDE7 inhibitors

Indexed keywords

2 [4 [6,7 DIETHOXY 2,3 BIS(HYDROXYMETHYL) 1 NAPHTHYL] 2 PYRIDYL] 4 (3 PYRIDYL) 1(2H) PHTHALAZINONE; 2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; AZO COMPOUND; HETEROCYCLIC COMPOUND; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE VII INHIBITOR; PHTALAZINONE DERIVATIVE; PURINE ANTAGONIST; PYRIMIDINE ANTAGONIST; SPIROQUINOZOLINONE DERIVATIVE; UNCLASSIFIED DRUG; YM 393059;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; DEGENERATIVE DISEASE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; INFLAMMATORY DISEASE; LIVER CLEARANCE; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; VOMITING;

EID: 56349091430     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.10.1127     Document Type: Review

References (82)

1. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006;109:366-98
2. Banner KH, Page CP. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Respir J 1995;8:996-1000
3. Essayan DM. Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomo-dulation. Biochem Pharmacol 1999;57:965-73
4. Kumar M, Bhattacharya. V. Cilostazol: a new drug in die treatment intermittent claudication. Recent Patents Cardiovasc Drug Discov 2007;2:181-5
5. Down G, Siederer S, Lim S, Daley-Yates P. Clinical pharmacology of Cilomilast. Clin Pharmacokinet 2006;45:217-33
6. Hatzimouratidis K. Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. Clin Interv Aging 2006;1:403-14
7. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006;5:660-70
8. Brandon NJ, Rotella DP. Potential CNS applications for PDEs inhibitors. Ann Rep Med Chem 2007;42:3-12
9. Halene TB, Siegel SJ. PDE inhibitors in psychiatry-future options for dementia, depression and schizophrenia? Drug Discov Today 2007;12:870-8
10. Rose GM, Hopper A, De Vivo M, Tehim A. Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 2005;11:3329-33
11. Ye YL, Shi WZ, Zhang WP, et al. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries. Eur J Pharmacol 2007;557:23-31
12. Kashimoto R, Kurimoto T, Miyoshi T, et al. Cilostazol promotes survival of axotomized retinal ganglion cells in adult rats. Neurosci Lett 2008;436:116-19
13. Devan BD, Pistell PJ, Daffin LW Jr, et al. Sildenafil citrate attenuates a complex maze impairment induced by intracerebroventricular infusion of the NOS inhibitor N Ω-nitro-L-arginine methyl ester. Eur J Pharmacol 2007;563:134-40
14. Schmidt CJ, Chapin DS, Cianfrogna J, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008;325:681-90
15. Ghavami A, Hirst WD, Novak TJ. Selective phosphodiesterase (PDE)-4 inhibitors: a novel approach to treating memory deficit? Drugs R D 2006;7:63-71
16. Available from: http://www.memorypharma.com/p_MEM1414.html
17. Pérez-Torres S, Cortés R, Tolnay M, et al. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp Neurol 2003;182:322-34
18. Li L, Yee C, Beavo JA. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 1999;283:848-51
19. Giembycz MA, Smith SJ. Phosphodiesterase 7A: a new therapeutic target for alleviating chronic inflammation? Curr Pharm. Des 2006;12:3207-20
20. Giembycz MA, Smith SJ. Phosphodiesterase 7 (PDE7) as a therapeutic target. Drugs Fut 2006;31:207-29
21. Smith SJ, Brookes-Fazakerley S, et al. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 2003;284:L279-89
22. Gardner C, Robas N, Cawkill D, Fidock M. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 2000;272:186-92
23. Miró X, Pérez-Torres S, Palacios JM, et al. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 2001;40:201-14
24. Reyes-Irisarri E, Pérez-Torres S, Mengod G. Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 2005;132:1173-85
25. Yang G, McIntyre KW, Townsend RM, et al. Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol 2003;171:6414-20
26. Nakata A, Ogawa K. Sasaki T, et al. Potential role of phosphodiesterase 7 in human T cell function: comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 2002;128:460-6
27. Vergne F, Bernardelli P, Chevalier E. PDE7 inhibitors: chemistry and potential therapeutic utilities. Ann Rep Med Chem 2005;40:227-41
28. Malik R, Bora RS, Gupta D, et al. Cloning, stable expression of human phosphodiesterase 7A and development of an assay for screening of PDE7 selective inhibitors. Appl Microbiol Biotechnol 2008;77:1167-73
29. Ke H, Wang H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr Top Med Chem 2007;7:391-403
30. Martínez A. Castro A, Gil C, et al. Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: first phosphodiesterase 7 inhibitors. J Med Chem 2000;43:683-9
31. Castro A, Jerez MJ, Gil C, Martinez A. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 2005;25:229-44
32. Lee R, Wolda S, Moon E, et al. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal 2002;14:277-84
33. Smith SJ, Cieslinski LB, Newton R, et al. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methylnitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+T-lymphocytes. Mol Pharmacol 2004;66:1679-89
34. Giembycz MA. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005;5:238-44
35. Yamamoto S, Sugahara S, Ikeda K, Shimizu Y. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. Eur J Pharmacol 2007;559:219-26
36. Pitts WJ, Vaccaro W, Huynh T, et al. Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorg Med Chem Lett 2004;14:2955-8
37. Kempson J, Pitts WJ, Barbosa J, et al. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships. Bioorg Med Chem Lett 2005;15:1829-33
38. Barnes MJ, Cooper N, Davenport RJ, et al. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg Med Chem Lett 2001;11:1081-3
39. Darwin Discovery Limited. 9-(1,2,3,4-Tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as PDE7 inhibitors. WO0068230; 2000
40. Bristol-Myers Squibb. Fused heterocyclic inhibitors of phosphodiesterase (PDE) 7. WO02087513; 2002
41. Bristol-Myers Squibb. Purine inhibitors of phosphodiesterase (PDE) 7. WO02102314; 2002
42. Bristol-Myers Squibb. Pyrimidine inhibitors of phosphodiesterase (PDE) 7. WO02102313; 2002
43. Ausbio Pharma. 1,3,5-Trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action. US007268128; 2007
44. Bristol-Myers Squibb. Quinazoline and pyrido[2,3-D]pyrimidine inhibitors of phosphodiesterase (PDE) 7. US007022849B2; 2006
45. Bristol-Myers Squibb. Quinazoline and pyrido[2,3-D]pyrimidine inhibitors of phosphodiesterase (PDE) 7. US20060116516A1; 2006
46. Celltech Chiroscience Ltd. Heterobiarylsulphonamides and their use as PDE7 inhibitors. WO0174786; 2001
47. Celltech Chiroscience Ltd. Sulphonamide derivatives. WO0198274; 2001
48. Smithkline Beecham Corp. Compounds and their use as PDE inhibitors. US0020156064; 2002
49. BYK Gulden Lomberg Chemische Fabrik GMBH. Dihydroisoquinolines as novel phosphodiesterase inhibitors. WO0240449; 2002
50. BYK Gulden Lomberg; Chemische Fabrik GMBH. (Dihydro)isoquinolines derivatives as phosphodiesterase inhibitors. WO0240450; 2002
51. Pekkinen M, Ahlström MEB, Riehle U, et al. Effects of phosphodiesterase 7 inhibition by RNA interference on the gene expression and differentiation of human mesenchymal stem cell-derived osteoblasts. Bone 2008;43:84-91
52. Daga PR, Doerksen RJ. Stereoelectronic properties of spiroquinazolinones in differential PDE7 inhibitory activity. J Comput Chem 2008;29:1945-54
53. Lorthiois E, Bernardelli P, Vergne F, et al. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1. Bioorg Med Chem Lett 2004;14:4623-6
54. Bernardelli P, Lorthiois E, Vergne F, et al. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives. Bioorg Med Chem Lett 2004;14:4627-31
55. Pfizer Ltd. Spirocyclic derivatives. WO2007063391; 2007
56. Warner-Lambert. New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors. WO2004/026818; 2004
57. Warner-Lambert. New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors. WO02/076953A1; 2002
58. Warner-Lambert. New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors. WO02074754; 2002
59. Warner-Lambert. Spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors. US2002/0198198A1; 2002
60. Pfizer Ltd. Use of PDE7 inhibitors for the treatment of neuropathic pain. WO2006092691; 2006
61. Merck Patent GMBH. Imidazole derivatives as phosphodiesterase VII inhibitors. WO0129049; 2001
62. Merck Patent GMBH. Isoxazole derivatives to be used as phosphodiesterase VII inhibitors. WO0132175; 2001
63. Merck Patent GMBH. Pyrrole derivatives as phosphodiesterase VII inhibitors. WO0132618; 2001
64. Merck Patent GMBH. Imidazopyridine derivatives as phosphodiesterase VII inhibitors. WO0134601; 2001
65. Merck Patent GMBH. Imidazole compounds used as phosphodiesterase VII inhibitors. WO0136425; 2001
66. Vergne F, Bernardelli P. Lorthiois E, et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies. Bioorg Med Chem Lett 2004;14:4607-13
67. Vergne F, Bernardelli P, Lorthiois E, et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives. Bioorg Med Chem Lett 2004;14:4615-21
68. Jones NA, Leport M, Holand T, et al. Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. Pulm. Pharmacol Ther 2007;20:60-8
69. Warner-Lambert. New thiadiazoles and their use as phosphodiesterase7-inhibitors. EP1193261A1; 2000
70. Warner-Lambert. (4,2-disubstituted-thiazol-5-yl)amine compounds as PDE7 inhibitors. WO03082839; 2003
71. Almirall Prodesfarma. 4-Aminothieno[2,3-d] pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors. WO2004065391; 2004
72. Vijayakrishnan L, Rudra S, Eapen MS, et al. Small-molecule inhibitors of PDE-IV and - VII in the treatment of respiratory diseases and chronic inflammation. Expert Opin Investig Drugs 2007;16:1585-99
73. Ukita T, Sugahara M, Terakawa Y, et al. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives. J Med Chem 1999;42:1088-99
74. Yamamoto S, Sugahara. S, Naito R, et al. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo. Eur J Pharmacol 2006;541:106-14
75. Yamamoto S, Sugahara S, Ikeda K, Shimizu, Y. Pharmacological profile of a novel phosphodiesterase inhibitor, YM-393059, on acute and chronic inflammation models. Eur J Pharmacol 2006;550:166-72
76. Bristol-Myers Squibb. Dual inhibitors of PDE7 and PDE4. WO02088079; 2002
77. Bristol-Myers Squibb. Dual inhibitors of PDE7 and PDE4. WO02088080; 2002
78. Bristol-Myers Squibb. Dual inhibitors of PDE7 and PDE4. US 20030104974; 2003
79. Altana Pharma AG. Novel phthalazinones. WO02085906; 2002
80. Castro A, Jerez MJ, Gil C, et al. CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem 2008;43:1349-59
81. Consejo Superior de Investigaciones Científicas and Instituto de Salud Carlos III. Compuesto inhibidor dual de las enzimas PDE7 y/o PDE4, composiciones farmacéuticas y sus aplicaciones. EP200700762; 2007
82. Celltech Chiroscience Ltd. WO0174786. PDE7 inhibitors. Expert Opin Ther Patents 2002;12:601-3